A US company has decided to withdraw an ALS drug from the market after it failed to show effectiveness in a clinical trial. The drug, which was being developed as a potential treatment for amyotrophic lateral sclerosis (ALS), did not meet the desired endpoints in the trial. The company made the decision to discontinue the development of the drug based on the trial results.
ALS, also known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. There is currently no cure for ALS, and treatment options are limited
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오: